anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Foxb1 -expressing neurons occur in the dorsal premammillary nucleus (PMd) and further rostrally in the parvafox nucleus, a longitudinal cluster of neurons in the lateral hypothalamus of rodents. The descending projection of these Foxb1+ neurons end in the dorsolateral part of the periaqueductal gray (dlPAG). The functional role of the Foxb1+ neuronal subpopulation in the PMd and the parvafox nucleus remains elusive. In this study, the activity of the Foxb1+ neurons and of their terminal endings in the dlPAG in mice was selectively altered by employing chemo- and optogenetic tools. Our results show that in whole-body barometric plethysmography, hM3Dq-mediated, global Foxb1+ neuron excitation activates respiration. Time-resolved optogenetic gain-of-function manipulation of the terminal endings of Foxb1+ neurons in the rostral third of the dlPAG leads to abrupt immobility and bradycardia. Chemogenetic activation of Foxb1+ cell bodies and ChR2-mediated excitation of their axonal endings in the dlPAG led to a phenotypical presentation congruent with a 'freezing-like' situation during innate defensive behavior.
The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
Of the 467 patients who received Altoprev in clinical studies, 18% were 65 years and older. In the clinical studies conducted with lovastatin immediate-release (EXCEL and AFCAPS/TexCAPS), 21% (3094/14850) of patients were ≥65 years of age. In pharmacokinetic studies with lovastatin immediate-release, the mean plasma level of HMG-CoA reductase inhibitory activity was shown to be approximately 45% higher in elderly patients between 70-78 years of age compared with patients between 18-30 years of age [see Clinical Pharmacology (12.3)].

Advanced age (≥65 years) is a risk factor for Altoprev-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving Altoprev for the increased risk of myopathy [see Warnings and Precautions (5.1)].
The invention discloses a pharmaceutical composition for treating lacunar infarction and a preparation method thereof. The pharmaceutical composition is prepared from herb of heterophyllous eupatorium, herb of bulbophyllum odoratissimum (Swartz) Lindl., rhizoma curcumae, radix cudramiae, roots of sarcococca ruscifolia stapf, lilium brownii, seeds of brassica campestris L., licorice roots, roots, leaves and fruit of zanthoxylum avicennae (Lam.)DC., India mustard seeds, musk, cortex eucommiae, retinervus citri reticulatae, fructus mume, roots of fissistigma oldhami (Hemsl.) Merr., leaves or root bark of apanea neriifolia (Sieb.Et Zucc.)Mez., retinervus luffae fructus, roots, leaves and flowers of viburnum cylindricum Buch.-Ham. ex D. Don, radix notoginseng, herba taraxaci, herb of polygonum sieboldii Meisn., membranaceous beautyleaf roots, herb or roots of abutilon indicum (L.)G. Don, rhizomes and tender leaves of smilax glauco-china Warb., flos carthami, herb of lygodium japonicum(Thunb.)Sw, stems and roots of dalbergia hancei Benth., radix gentianae macrophyllae, ovate leaf holly bark and roots and herb of cyananthus argernteus Marg.. The pharmaceutical composition has the effects of promoting blood circulation to remove blood stasis, inducing resuscitation with herbal aromatics, dredging the channels, relieving hydrocephalus and improving microcirculation and has the advantages of being capable of rapidly achieving the effects, high in effective rate, exact in treatment effect, short in treatment course, capable of enhancing the effects, reducing toxicity and achieving multi-target treatment, low in cost and the like.
PURPOSE: To incorporate salicylic acid in the form of an unneutralized free acid into cosmetic compsn. having neutral pH value. CONSTITUTION: This cosmetic compsn. consists of film forming lipid dispersed in the form of liposome, unneutralized salicylic acid existing locally in the bimolecular film of the liposome, other cosmetic component existing in the film or in an aq. phase at the outside or inside of the film or existing properly in both the film and the aq. phase, a water-soluble org. base impermeable into the film and the balance water.
OBJECTIVES: I. Determine the safety of CCI-779 in patients with androgen-independent prostate cancer. II. Determine the effects of CCI-779 on prostate-specific antigen levels in these patients. III. Assess the pharmacokinetic parameters of CCI-779 in these patients. IV. Assess the possible pharmacodynamic relationship of CCI-779 with clinical response in these patients. V. Determine the impact of CCI-779 on the quality of life in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 4 arms. Arm I: Patients receive low-dose CCI-779 IV over 30 minutes weekly. Arm II: Patients receive high-dose CCI-779 IV over 30 minutes weekly. Arm III: Patients receive low-dose placebo IV over 30 minutes weekly. Arm IV: Patients receive high-dose placebo IV over 30 minutes weekly. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease while receiving placebo may cross over to the equivalent dose of CCI-779. Quality of life is assessed at baseline; at weeks 4, 8, 12, 24, and 36; and at final/cross-over visit. Patients are followed every 3 months.

PROJECTED ACCRUAL: Approximately 150 patients will be accrued for this study.
An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
Inclusion criteria : being currently edentulous within at least within the maxillary arch, literate French speakers, willing and able to complete the survey in a single sitting. Clinical data collection was made by a unique examiner and concerned length of edentulism, antagonist arch, existence of preextraction data, smile attractivity opinion. The respondents completed a questionnaire identifying their age, sex, educational and income level. Patients were also asked for their denture look preference among 4 esthetic projects: 1) restoring pre-extraction (dentate) looking, 2) restoring actual denture looking, 3) creating natural looking, 4) creating perfect looking, 5) no opinion. Each project was explained similarly by the same examiner. Statistical analysis using a Pearson Chi-squared test at a 0.05 level of significance was conducted for associations between esthetic projects preference and tested variables.
In- and out-patients with left ventricular assist device (LVAD) will be recruited to participate. On consent to participate, patients will be randomized to either moderate continuous (MCT) or interval (IT) training. An initial cardiopulmonary exercise test (CPET) will be performed to assess exercise intensity levels using a ramp protocol. Baseline quality of life (KCCQ score), echocardiographic and LVAD parameters, lab works, including NTproBNP, a 6min walk distance (6 MWD) will be assessed. Patients will then receive 6 weeks of supervised training in our facility (3x/week, 30min each). Following these sessions CPET, lab works, KCCQ assessment, 6 MWD, and echocardiography will be performed to assess improvement of exercise capacity.

Patients in the MCT group will receive 20min of moderate, continuous bicycle training at an intensity of 50-60% of VO2peak, the IT group will increase exercise density by increasing the duration of intense bouts (80-90% of VO2peak) over the weeks. All groups will receive an additional 10 minutes of resistance training (total exercise time 30 minutes in both groups). Improvement of VO2peak and quality of life (KCCQ score) between the groups will be assessed.
Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
PROBLEM TO BE SOLVED: To prepare a sheet-shaped pack material, excellent in the effect for preventing the adhering of a sticky resin to fingers by subjecting both the obverse side and the reverse side of a peel off-type sheet-shaped pack material to a water repelling treatment. SOLUTION: This peel off-type sheet-shaped pack material is treated with a water repelling agent both on the surface closely adhering to the skin and the surface of the opposite side. The thickness of a tacky agent layer of the pack material is preferably 10-2000μm. As a method for the water repelling treatment, it is cited that a sheet-shaped pack material is prepared, and subsequently a water repelling agent (preferably, a perfluoroalkylated resin, a perfluoroalkylsilane, etc.) is applied on both the surface closely adhering to the skin and the surface of the opposite side, etc. The amount of the water- repelling agent to be applied is preferably the amount achieving a contact angle of >=60 degree, preferably >=90 degree when water is used.  Thus obtained pack material is excellent in the activity for removing sebum and aged keratin, and effective for preventing fingers from being soiled.
All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
Approximately 90% of polyps are smaller than 10 mm. Given the risk of transformation of adenomas into invasive cancer over years, it is important that these adenomas are completely resected.

This will be a double-blind, prospective, randomized controlled trial. All eligible patients referred for a colonoscopy will be able to participate. There will be 2 treatment arms, one arm will be treated with a thin wire snare and the other with a thick wire snare. Patients will be randomised through a computer generated programme and blinded for the type of snare used. The treatment arm will be disclosed to the proceduralist after introduction of the colonoscope into the rectum. After resection of the polyp the defect will be carefully examined by the proceduralist. In case of suspicion of residual adenomatous tissue, a re-excision will be performed. If there's a protrusion noticeable at the resection site, this will be biopsied. Ultimately, the margins of the defect will be biopsied on either side for histological confirmation of complete removal.
COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
The most direct treatment of hot flushes may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity of hot flushes in preliminary trials. Also several Selective Serotonin Reuptake Inhibitors (SSRIs) and other similar compounds have been investigated to manage hot flushes, confirming the role of the serotonergic system. In the present trial, the efficacy and safety of four different doses of esmirtazapine compared to placebo were investigated in women with moderate to severe vasomotor symptoms associated with the menopause. The primary objective of this trial was to demonstrate superior efficacy in at least one of the four doses of esmirtazapine as compared to placebo on the four following co-primary endpoints: 1) the mean change from baseline in average daily frequency of moderate and severe vasomotor symptoms at Week 4; 2) the mean change from baseline in average daily frequency of moderate and severe vasomotor symptoms at Week 12; 3) the mean change from baseline in average daily severity of moderate and severe vasomotor symptoms at Week 4; 4) the mean change from baseline in average daily severity of moderate and severe vasomotor symptoms at Week 12. The number and severity of hot flushes was recorded by means of electronic diary by the subjects.
This 30-45 minutes Qualtrics-based, digital program uses stories, interactive activities, and engaging graphics to teach youths one core principle: by practicing the positive opposite of unhelpful behaviors (e.g., engaging with rather than avoiding feared stimuli), one can, over time, change their mood, thoughts, and actions. The intervention is comprised of four main sections: 1) An introduction to PTO; (2) Testimonials from young people who have been helped by PTO; (3) Learning how to Practice the Opposite through online activities. (4) Planning how to continue to Practice the Opposite in the participant's life. Of note, after being removed from the waitlist at the clinic and contacted to begin treatment, participants will still receive treatment as usual from the clinic.
Described herein is a method of reversing or preventing a formation or enlargement of an axonal spheroid. The method includes introducing into a neuron affected by the formation or enlargement of the axonal spheroid, a compound that downregulates an expression level or an activity of PLD3. Also described herein is a method of treating or preventing a neurodegenerative condition in a subject in need thereof. The method includes administering to the subject a compound that downregulates an expression level or an activity of PLD3 in a neuron cell affected by the neurodegenerative condition. Further described herein is a pharmaceutical composition for treating a neurodegenerative condition in a subject. The pharmaceutical composition includes a compound that downregulates an expression level or an activity of PLD3 in a neuron cell affected by the neurodegenerative condition; and a pharmaceutically acceptable carrier.
Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
The invention relates to a traditional Chinese medicine preparation, and specifically relates to a coaptation medicine used for treating bone fracture and bone cracking, and a preparation method thereof. The coaptation medicine is prepared form following medicine raw materials, 15 to 20g of drynaria baronii, 15 to 20g of safflower carthamus, 20g of native copper, 15g of mastic, 15g of myrrh, 10 to 15g of Chinese Polyphaga, 30g of dragon's blood, 30g of pseudo-ginseng, and 10g of borneol. According to the preparation method, the nine traditional Chinese medicine ingredients are fully mixed, and an obtained mixture is smashed using a pulverizer to a particle size higher than 150 meshes. The coaptation medicine is a pure Chinese medicine preparation, is capable of invigorating blood and stopping bleeding, promoting the circulation of qi, relieving swelling and pain, promoting rapid recovery and regeneration of damaged periosteum, osteocyte, and bone nerve, and promoting generation of new bone bud. Recovery can be realized via one month consumption of the coaptation medicine. After 20 years of clinical application of the coaptation medicine, no toxic or side effect is observed; the preparation method is simple; cost is low; relapse is not easily caused after recovery; the coaptation medicine is convenient for consumption; curative effects are realized quickly; and effects are excellent.
The invention relates to 5,10-methylene-(6R)-,-(6S)-or (6R,S)-tetrahydrofolate (MTHF) pharmaceutical compounds whose stability is due to the adjustment thereof to a basic pH value and to a simultaneous citrate use. Said stabilisation is self-producible in the absence of a reducing agent. Said invention is particularly suitable for preparing lyophilization solution or lyophilisates or dry powders and dry mixtures since the stable MTHF solutions can be filled at the high concentration thereof into corresponding recipients like, for example vials, ampoules etc. Said lyophilisates are surpassingly storable and stable. They are easily reconstituted by adding water or aqueous solutions, thereby providing diluted injection solutions ready for use with an excellent stability. Said invention also makes it possible to produce highly concentrated calcium or acid MTHF salts, even difficult-to-dissolve, in the form of isotonic physiologically compatible solutions.
PURPOSE: To obtain an antibacterial cephalosporin compd. in a high yield without using a large excess of an acid halide by a novel process wherein a specific hydroxymethyl Δ 3 -cephalosporin compd. is used as a starting material.  
     CONSTITUTION: First, 3-hydroxymethyl Δ 3 -cephalosporin compd. having a carboxyl group at the 2-position [pref. a compd. of formula I (wherein R is H or acyl; and R 2  is H or lower alkoxy)] is converted into an org. salt by the treatment with an org. base (pref. triethylamine). Then, the 3-hydroxymethyl substituent of the org. salt is acylated with an acylating agent (pref. an acid fluoride) in a nonaq. org. solvent (pref. methylene chloride), and the resultant product is esterified or is converted into a salt, a hydrate, or a hydrate of salt, thus giving the objective compd. of formula II (wherein R 3  is a carbocyclic aryl group of which the carbocycle is substd. by a group selected from among hydroxyl, amino, or the like; and R is H or carboxyl-acid-protecting group), a salt thereof, or a hydrate thereof wherein R is H. 
     COPYRIGHT: (C)1995,JPO
BACKGROUND: Compartment syndrome is a well-known phenomenon that is most commonly reported in the extremities. However, paralumbar compartment syndrome is rarely described in available literature. The authors present a case of paralumbar compartment syndrome after high intensity deadlifting.
CASE PRESENTATION: 53-year-old male who presented with progressively worsening low back pain and paresthesias one day after high-intensity deadlifting. Laboratory testing found the patient to be in rhabdomyolysis; he was admitted for intravenous fluid resuscitation and pain control. Orthopedics was consulted, and Magnetic Resonance Imaging revealed significant paravertebral edema and loss of muscle striation. Given the patient's lack of improvement with intravenous and oral pain control, clinical and radiographic findings, there was significant concern for acute paralumbar compartment syndrome. The patient subsequently underwent urgent fasciotomy of bilateral paralumbar musculature with delayed closure.
CONCLUSION: Given the paucity of literature on paralumbar compartment syndrome, the authors' goal is to promote awareness of the diagnosis, as it should be included in the differential diagnosis of intractable back pain after high exertional exercise. The current literature suggests that operative cases of paralumbar compartment syndromes have a higher rate of return to pre-operative function compared to those treated non-operatively. This case report further supports this notion. The authors recommend further study into this phenomenon, given its potential to result in persistent chronic exertional pain and irreversible tissue damage.
Tumor metastasis remains a major challenge in cancer management. Among various treatment strategies, immune cell-based cancer therapy holds a great potential for inhibiting metastasis. However, its wide application in cancer therapy is restricted by complex preparations, as well as inadequate homing and controllability. Herein, we present a groundbreaking approach for bioorthogonally manipulating tumor-NK (natural killer) cell assembly to inhibit tumor metastasis. Multiple dibenzocyclootyne (DBCO) groups decorated long single-stranded DNA were tail-modified on core-shell upconversion nanoparticles (CSUCNPs) and condensed by photosensitive chemical linker (PC-Linker) DNA to shield most of the DBCO groups. On the one hand, the light-triggered DNA scaffolds formed a cross-linked network by click chemistry, effectively impeding tumor cell migration. On the other hand, the efficient cellular assembly facilitated the effective communication between tumor cells and NK-92 cells, leading to enhanced immune response against tumors and further suppression of tumor metastasis. These features make our strategy highly applicable to a wide range of metastatic cancers.
Formation of a drug into microspheres by an oil-on-water solvent evaporation process in which a mixed solvent of at least one water-insoluble solvent and at least one water-miscible solvent is used as a solvent of an oil phase. A fatty acid or a salt thereof or at least one glycerin fatty acid ester and/or at least one propylene glycol fatty acid ester are added to the mixed solvent. The oil phase may also comprise the mixed solvent; a fatty acid or a salt thereof; and at least one glycerin fatty acid ester and/or at least one propylene glycol fatty acid ester. This oil phase is mixed and emulsified with an aqueous phase to form an oil-in-water emulsion. The emulsion with a drug contained therein is then subjected to an oil-in water solvent evaporation to produce the microspheres. The resulting drug-containing microspheres contain the drug at a high concentration and slowly release from the initial stage after administration.
FIELD: veterinary. SUBSTANCE: preparation for piglet treatment with gastroenteric diseases has hydrosulfate, polyvinylethynyltrimethylpiperidol, iodine, potassium iodide, polymyxine and distilled water. Preparation is given orally to piglets at the dose 2.0-2.2 ml per kg animal body mass, twice per 24 hr for 3-4 days. Preparation is harmless, does not show negative effects on the physiological, hematological and nonspecific factors of animal immunity. Effectiveness of preparation is 95-98%. Preparation can be used for treatment of gastroenteric diseases in animals. EFFECT: enhanced effectiveness of preparation.